<DOC>
	<DOCNO>NCT00637494</DOCNO>
	<brief_summary>Approximately 450 patient randomized receive Mifepristone placebo 7 day follow antidepressant . The purpose compare efficacy Mifepristone follow antidepressant versus placebo follow antidepressant reduce psychotic symptom patient diagnosis psychotic depression .</brief_summary>
	<brief_title>A Study Mifepristone v . Placebo Treatment Patients With Major Depression With Psychotic Features</brief_title>
	<detailed_description>Up 450 patient psychotic depression randomly assign receive either Mifepristone match placebo . Patients assess Investigator site staff screen study day . A single antidepressant select list approve drug administer administration investigational drug . Adverse event , laboratory assessment , electrocardiogram , physical examination use assess safety .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<criteria>Have provide write consent participate study prior study procedure understand free withdraw study time . Patients must able read understand consent form , complete studyrelated procedure , communicate study staff Have DSMIV TR diagnosis Major Depressive Disorder Psychotic Features ( DSMIV 296.24 296.34 ) , clinically symptomatic illness Have prespecified minimum score standardize psychiatric rating scale baseline Have take exclude medication least 7 day prior randomization Have negative pregnancy test If postmenopausal â‰¥ 2 year surgically sterile ( 6 month postsurgery ) , must consent ( patient partner ) utilize two medically acceptable method contraception , one barrier method , throughout entire study period 3 month study complete Have primary psychiatric diagnosis psychotic depression . Have major medical problem , opinion Investigator would place patient undue risk . Have undergone electroconvulsive therapy within 3 month prior randomization Have hospitalization due suicide attempt within 45 day prior randomization Are female childbearing age , unable unwilling use two medically acceptable method contraception study three month study completion , one must barrier method Are female pregnant lactating Are currently take exclude medication Have use drug abuse within 30 day prior screen , per patient report urine drug screen Have history active drug alcohol abuse within 3 month dependence within 6 month prior screen Are opinion Investigator immediate risk suicide , risk harm others Have receive investigational therapy ( drug , vaccine , biological agent device ) within 6 month prior randomization Have previously participate clinical trial Mifepristone ( C1073 ) Have history allergic reaction Mifepristone ( C1073 ) Are Investigator 's opinion appropriate participation study may capable follow study schedule reason Are patient employee study unit family member , student work study unit , family member Investigator Corcept Therapeutics .</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>psychotic depression</keyword>
	<keyword>major depression psychotic feature</keyword>
	<keyword>psychosis</keyword>
</DOC>